NasdaqGM - Delayed Quote • USD
Sensei Biotherapeutics, Inc. (SNSE)
At close: April 22 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -0.27 | -0.24 | -1.01 | -1.05 |
| Low Estimate | -0.31 | -0.32 | -1.29 | -1.2 |
| High Estimate | -0.24 | -0.14 | -0.65 | -0.87 |
| Year Ago EPS | -0.33 | -0.31 | -1.22 | -1.01 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.36 | -0.33 | -0.34 | -0.31 |
| EPS Actual | -0.33 | -0.31 | -0.28 | -0.3 |
| Difference | 0.03 | 0.02 | 0.06 | 0.01 |
| Surprise % | 8.30% | 6.10% | 17.60% | 3.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.27 | -0.24 | -1.01 | -1.05 |
| 7 Days Ago | -0.27 | -0.24 | -1.01 | -1.05 |
| 30 Days Ago | -0.27 | -0.24 | -1.01 | -1.05 |
| 60 Days Ago | -0.28 | -0.25 | -1.09 | -1.14 |
| 90 Days Ago | -0.28 | -0.25 | -1.08 | -1.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SNSE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 18.20% | -- | -- | 0.20% |
| Next Qtr. | 22.60% | -- | -- | 9.40% |
| Current Year | 17.20% | -- | -- | 4.40% |
| Next Year | -4.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | HC Wainwright & Co.: Buy | 12/4/2023 |
| Initiated | Citigroup: Buy | 12/13/2022 |
| Upgrade | Oppenheimer: Perform to Outperform | 10/3/2022 |
| Maintains | Piper Sandler: Overweight | 3/10/2022 |
| Downgrade | Berenberg: Buy to Hold | 7/1/2021 |
| Downgrade | Oppenheimer: Outperform to Perform | 6/29/2021 |
Related Tickers
SEER Seer, Inc.
1.6700
+0.60%
BRNS Barinthus Biotherapeutics plc
2.6200
+3.76%
LVTX LAVA Therapeutics N.V.
2.8500
+5.17%
BOLT Bolt Biotherapeutics, Inc.
1.1100
0.00%
ACHL Achilles Therapeutics plc
0.7900
-0.50%
TARA Protara Therapeutics, Inc.
3.0500
+15.53%
AADI Aadi Bioscience, Inc.
1.9000
+3.26%
SPRB Spruce Biosciences, Inc.
0.6920
-1.20%
EXTX.OL EXACT Therapeutics AS
7.00
0.00%
KROS Keros Therapeutics, Inc.
55.78
-4.29%